ReviewPharmaceutics2025
Pathophysiology and Treatment of Psoriasis: From Clinical Practice to Basic Research.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Psoriasis and Psoriatic Arthritis in Pregnancy: Current Evidence and Clinical Considerations.Cureus · 2026Review
- Potential Blood Biomarkers Predicting Treatment Response in Psoriasis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Biomarkers for diagnosis, disease progression, and therapeutic response in psoriasis vulgaris: A mini-review.Narra J · 2026Review
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Inflammatory burden and cardiovascular risk stratification across psoriasis severity stages.Journal of medicine and life · 2026Article
- Integrative Multi-Omics Mendelian Randomization Identifies BLMH as a Keratinocyte-Enriched Protective Candidate Gene and Potential Therapeutic Target in Psoriasis.Journal of inflammation research · 2026Article
- The Impact of Vehicle Occlusivity on Skin Delivery and Activity of a Janus Kinase Inhibitor: Comparison of Oil-Based Formulations.Pharmaceutics · 2025Article
- Lights and Shadows of Nutrient-Driven Keratinocyte Inflammation in Psoriasis.International journal of molecular sciences · 2025Review
- Methylarginine Levels in Chronic Inflammatory Skin Diseases-The Role of L-Arginine/Nitric Oxide Pathway.Journal of clinical medicine · 2025Review
- Tracing Five Decades of Psoriasis Pharmacotherapy: A Large-Scale Bibliometric Investigation with AI-Guided Terminology Normalization.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications.AAPS PharmSciTech · 2025Review
- Dietary Principles, Interventions and Oxidative Stress in Psoriasis Management: Current and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Unravelling the gut-skin axis: the role of gut microbiota in pathogenesis and management of psoriasis.Inflammopharmacology · 2025Review
- Review
- Does ChatGPT help patients access reliable and comprehensive information about psoriasis?Proceedings (Baylor University. Medical Center) · 2025Article
- Relative Fat Mass and Psoriasis Risk: Evidence from NHANES 2009-2014.Journal of multidisciplinary healthcare · 2025Article
- Investigation of the mechanism of Xiaoyin Jiedu Yin in the treatment of psoriasis based on bioinformatics, machine learning.Frontiers in chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Psoriasis, a chronic inflammatory dermatosis, represents a significant clinical challenge due to its complex pathogenesis and the limitations of existing therapeutic strategies. Current psoriasis diagnoses are primarily clinician-dependent, with instrumental diagnostics serving as adjuncts. Ongoing research is progressively deciphering its molecular underpinnings; the future of psoriasis diagnostics may involve genetic and immunological profiling to pinpoint biomarkers, enabling more accurate and timely interventions. The administration of psoriasis medications, whether oral, injectable, or topical, is associated with a range of side effects and compliance issues. Topical medications, despite their advantages in patient compliance and reduced systemic side effects, are hindered by the altered skin barrier in psoriasis, which impedes effective drug penetration and retention. In recent years, the development of novel transdermal drug delivery systems represents a promising frontier in psoriasis management. Nanotechnology-, microneedle- and dressing-based systems have demonstrated the potential for improved skin penetration, enhanced bioavailability, or extended retention time. Here, we will focus on the latest insights into the etiology, diagnostic methodologies, and therapeutic approaches for psoriasis, with a particular emphasis on the evolution and challenges of novel transdermal drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.